Watchlist Price Alert

Spero Therapeutics Inc. (SPRO)

NASDAQ: SPRO · Real-Time Price · USD

2.50

0.37 (17.37%)

At close: May 30, 2025, 3:59 PM

2.53

1.13%

After-hours: May 30, 2025, 05:58 PM EDT

17.37% (1D)

Bid	2.52
Market Cap	139.87M
Revenue (ttm)	34.72M
Net Income (ttm)	-55.9M
EPS (ttm)	-1.28
PE Ratio (ttm)	-1.95
Forward PE	-1.91
Analyst	Hold

Ask	2.56
Volume	24,107,543
Avg. Volume (20D)	3,204,917
Open	2.50
Previous Close	2.13
Day's Range	2.35 - 2.80
52-Week Range	0.51 - 2.80
Beta	0.23

About SPRO

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SPRO

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SPRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

4 days ago

+244.57%

Spero Therapeutics shares are trading higher after... Unlock content with Pro Subscription

7 months ago

-1.53%

Spero Therapeutics shares are trading lower after the company announced its Phase 2a proof-of-concept study of SPR720 did not meet its primary endpoint.

News

3 days ago · zacks.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.

4 days ago · benzinga.com

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for...

2 weeks ago · zacks.com

Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.24 per share a year ago.

2 months ago · seekingalpha.com

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Shai Biran - Senior Director Investor Relations Esther Rajavelu - Interim Chief ...

2 months ago · zacks.com

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to earnings of $0.96 per share a year ago.